OnKure Therapeutics, Inc. (OKUR) - Total Liabilities
Based on the latest financial reports, OnKure Therapeutics, Inc. (OKUR) has total liabilities worth $6.41 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
OnKure Therapeutics, Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how OnKure Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See OnKure Therapeutics, Inc. (OKUR) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
OnKure Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of OnKure Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
S H L Telemedicine Ltd
SW:SHLTN
|
Switzerland | CHF40.82 Million |
|
Coreana Cosmetics Co.Ltd
KQ:027050
|
Korea | ₩16.69 Billion |
|
SK Discovery Co Ltd
KO:006125
|
Korea | ₩8.93 Trillion |
|
Bayview Acquisition Corp Class A Ordinary Shares
NASDAQ:BAYA
|
USA | $6.26 Million |
|
Laird Superfood Inc
NYSE MKT:LSF
|
USA | $7.76 Million |
|
Phaos Technology Holdings (Cayman) Limited
NYSE MKT:POAS
|
USA | $3.90 Million |
|
Lipum AB
ST:LIPUM
|
Sweden | Skr11.63 Million |
|
Maven Wireless Sweden AB
ST:MAVEN
|
Sweden | Skr54.94 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down OnKure Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of OnKure Therapeutics, Inc..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OnKure Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OnKure Therapeutics, Inc. (2020–2024)
The table below shows the annual total liabilities of OnKure Therapeutics, Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $11.08 Million | -91.95% |
| 2023-12-31 | $137.58 Million | +95.37% |
| 2022-12-31 | $70.42 Million | +933.57% |
| 2021-12-31 | $6.81 Million | -93.00% |
| 2020-12-31 | $97.34 Million | -- |
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, includin… Read more